Decreased risk of developing cancer in subjects carrying SLC52A3 rs13042395 polymorphism: proof from a meta-analysis.
OBJECTIVE
This study aimed to conduct a meta-analysis to explore the association between SLC52A3 rs13042395 polymorphism and cancer risk.


METHODS
A comprehensive literature search was performed to confirm the relationship evaluated using STATA 12.0 software.


RESULTS
Overall, SLC52A3 rs13042395 C>T polymorphism was associated with cancer risk in two genetic models (TT vs CC: odds ratio: 0.86; 95% CI: 0.80-0.93; p < 0.001, TT vs CC + CT: odds ratio: 0.88; 95% CI: 0.82-0.95; p = 0.001). Significant associations were found between SLC52A3 rs13042395 polymorphism and decreased cancer risk among esophageal cancer, Asians, female, normal BMI and old age groups. No significant associations were observed in alcohol and smoking groups.


CONCLUSIONS
SLC52A3 rs13042395 C>T polymorphism might be a potential biomarker for cancer susceptibility.
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Jun
J
Li
Department of Neurosurgery, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Shilong
S
Wang
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Man
M
Li
Department of Neurosurgery, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Hui
H
Xu
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Dandan
D
Li
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Can
C
Yin
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
Jin
J
Zhao
Department of Pathology, Shihezi University School of Medicine & The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.|Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100000, China.
Feng
F
Li
D044466:Asian People / Q000235:genetics; D016208:Databases, Factual; D004198:Disease Susceptibility; D004938:Esophageal Neoplasms / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D005838:Genotype; D006720:Homozygote; D006801:Humans; D026901:Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
D026901:Membrane Transport Proteins; C548553:SLC52A3 protein, human
SLC52A3; association; cancer; meta-analysis; rs13042395